# Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

> **NCT04624204** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 672 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab 200 mg
- **BIOLOGICAL:** Pembrolizumab 400 mg
- **DRUG:** Pembrolizumab placebo (saline)
- **DRUG:** Pembrolizumab placebo (saline)
- **DRUG:** Olaparib 300 mg BID
- **DRUG:** Olaparib matching placebo
- **DRUG:** Etoposide 100 mg/m^2
- **DRUG:** Platinum, investigator's choice
- **RADIATION:** Standard Thoracic Radiotherapy
- **RADIATION:** Prophylactic Cranial Irradiation (PCI)

## Key facts

- **NCT ID:** NCT04624204
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-08
- **Primary completion:** 2027-10-28
- **Final completion:** 2027-10-28
- **Target enrollment:** 672 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624204, "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04624204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*